New combo therapy targets recurrent ovarian cancer
NCT ID NCT03734692
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for women whose ovarian cancer has come back. It combines chemotherapy and immunotherapy given directly into the abdomen with a drug given through a vein. The goal is to see if this approach can shrink or eliminate tumors. The study involves 24 participants and is currently active but not recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER RECURRENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, 15213, United States